CHOP对比GEM-P方案治疗初治外周T细胞淋巴瘤(CHEMO-T):一项2期多中心随机开放标签试验
该2期多中心随机开放标签试验纳入87例初治外周T细胞淋巴瘤患者,比较CHOP与GEM-P方案。GEM-P组确认或未确认完全缓解率46%(17/37)低于CHOP组62%(23/37),差异未达统计学显著(OR 0.52,95%CI 0.21-1.31;p=0.164),试验提前终止,CHOP仍为参考方案。
要点
- GEM-P组完全缓解或未确认完全缓解17/37(46%),CHOP组23/37(62%),OR 0.52(95%CI 0.21-1.31;p=0.164),未达统计学显著。
- 3级及以上不良事件:中性粒细胞减少CHOP组17例(40%)vs GEM-P组9例(20%);血小板减少CHOP组4例(10%)vs GEM-P组13例(30%);发热性中性粒细胞减少CHOP组12例(29%)vs GEM-P组3例(7%)。
- GEM-P组2例(5%)死于肺部感染,CHOP组无死亡。
核心结论
- GEM-P组确认或未确认完全缓解人数与CHOP组无显著差异,表明GEM-P在该结局上并不优于CHOP。
- CHOP应继续作为初治外周T细胞淋巴瘤的参考方案。
研究设计与样本
- 2期、平行组、多中心、开放标签随机试验,在47家医院开展(英国46家,澳大利亚1家)。
- 纳入87例患者,随机分配至CHOP组43例或GEM-P组44例,按外周T细胞淋巴瘤亚型和国际预后指数分层(1:1)。
- 主要终点为完成研究化疗时基于CT的完全缓解或未确认完全缓解比例,旨在检测GEM-P较CHOP的20%优效性。
主要发现
- 中位随访27.4个月(IQR 16.6-38.4),CHOP组可评估37例中23例(62%)达到完全缓解或未确认完全缓解,GEM-P组可评估37例中17例(46%)达到(OR 0.52,95%CI 0.21-1.31;p=0.164)。
- 3级及以上不良事件:中性粒细胞减少CHOP组17例(40%)vs GEM-P组9例(20%);血小板减少CHOP组4例(10%)vs GEM-P组13例(30%);发热性中性粒细胞减少CHOP组12例(29%)vs GEM-P组3例(7%)。
- 研究期间2例患者(5%)死亡,均在GEM-P组,死于肺部感染。
关键数值与推荐
- CHOP方案:静脉环磷酰胺750 mg/m²、多柔比星50 mg/m²、长春新碱1.4 mg/m²(最大2 mg)第1天,口服泼尼松龙100 mg第1-5天,每21天一次,共6周期。
- GEM-P方案:静脉吉西他滨1000 mg/m²第1、8、15天,顺铂100 mg/m²第15天,口服或静脉甲泼尼龙1000 mg第1-5天,每28天一次,共4周期。
临床怎么用
- CHOP应继续作为初治外周T细胞淋巴瘤的参考方案。
局限性
- 独立数据监测委员会2016年11月计划性非盲疗效数据审查显示GEM-P组确认或未确认完全缓解人数非显著劣于CHOP,试验提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in previously untreated patients. METHODS: We did a phase 2, parallel-group, multicentre, open-label randomised trial in 47 hospitals: 46 in the UK and one in Australia. Participants were patients aged 18 years and older with bulky (tumour mass diameter >10 cm) stage I to stage IV disease (WHO performance status 0-3), previously untreated peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, enteropathy-associated T-cell lymphoma, or hepatosplenic γδ T-cell lymphoma. We randomly assigned patients (1:1) stratified by subtype of peripheral T-cell lymphoma and international prognostic index to either CHOP (intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2 mg] on day 1, and oral prednisolone 100 mg on days 1-5) every 21 days for six cycles; or GEM-P (intravenous gemcitabine 1000 mg/m2 on days 1, 8, and 15, cisplatin 100 mg/m2 on day 15, and oral or intravenous methylprednisolone 1000 mg on days 1-5) every 28 days for four cycles. The primary endpoint was the proportion of patients with a CT-based complete response or unconfirmed complete response on completion of study chemotherapy, to detect a 20% superiority of GEM-P compared with CHOP, assessed in all patients who received at least one cycle of treatment and had an end-of-treatment CT scan or reported clinical progression as the reason for stopping trial treatment. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov (NCT01719835) and the European Clinical Trials Database (EudraCT 2011-004146-18). FINDINGS: Between June 18, 2012, and Nov 16, 2016, we randomly assigned 87 patients to treatment, 43 to CHOP and 44 to GEM-P. A planned unmasked review of efficacy data by the independent data monitoring committee in November, 2016, showed that the number of patients with a confirmed or unconfirmed complete response with GEM-P was non-significantly inferior compared with CHOP and the trial was closed early. At a median follow-up of 27·4 months (IQR 16·6-38·4), 23 patients (62%) of 37 assessable patients assigned to CHOP had achieved a complete response or unconfirmed complete response compared with 17 (46%) of 37 assigned to GEM-P (odds ratio 0·52, 95% CI 0·21-1·31; p=0·164). The most common adverse events of grade 3 or worse in both groups were neutropenia (17 [40%] with CHOP and nine [20%] with GEM-P), thrombocytopenia (4 [10%] with CHOP and 13 [30%] with GEM-P, and febrile neutropenia (12 [29%] with CHOP and 3 [7%] with GEM-P). Two patients (5%) died during the study, both in the GEM-P group, from lung infections. INTERPRETATION: The number of patients with a complete response or unconfirmed complete response did not differ between the groups, indicating that GEM-P was not superior for this outcome. CHOP should therefore remain the reference regimen for previously untreated peripheral T-cell lymphoma. FUNDING: Bloodwise and the UK National Institute of Health Research.
引用
- Gleeson M, Peckitt C, To YM, et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018. PMID: 29703335. doi:10.1016/S2352-3026(18)30039-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。